Choraria, Nirmalkumar http://orcid.org/0000-0002-8336-666X
Rangarajan, Savita http://orcid.org/0000-0001-7367-133X
John, M. Joseph http://orcid.org/0000-0003-0820-7332
Apte, Shashikant
Gupta, Pritam
Pai, Seema
Chand, Rohit
Parvatini, Shyam
Ramakanth, G. S. H.
Rupon, Jeremy
Chhabra, Amit
Muley, Hitesh Bhaskarrao
Simoneau, Damien
Funding for this research was provided by:
Pfizer (Pfizer)
Article History
Received: 1 June 2022
Accepted: 19 September 2022
First Online: 27 November 2022
Declarations
:
: Nirmalkumar Choraria and Shashikant Apte have no conflicts to disclose. Savita Rangarajan has served on an advisory board for Pfizer and for Sanofi Sigilon; has served on a speakers’ bureau for Pfizer and Takeda; and has served as a consultant for Reliance Life Sciences. M. Joseph John has served as a speaker/consultant or advisory board member, and/or received research support for attendance at educational meetings from Dr Reddy’s Lab, Grifols, Janssen, Mylan, Novo Nordisk, Pfizer, Roche, and Takeda. Pritam Gupta, Shyam Parvatini, Rohit Chand, Seema Pai, G. S. H. Ramakanth, Jeremy Rupon, Chhabra Amit, Hitesh Bhaskarrao Muley, and Damien Simoneau are employees of Pfizer Inc. and may own stock/options in the company.
: The final protocol, amendment and informed consent documentation were reviewed and approved by the IRB/EC at each of the investigational centers participating in the study. Investigators were required to inform their IRBs/ECs of the study’s progress and occurrence of any serious and/or unexpected adverse events.
: All participants or their parents/guardians provided written informed consent.